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Post-transplant renal function in the first year predicts long-term Renal transplantation remains the treatment of choice
kidney transplant survival. for end-stage renal disease (ESRD) in regards to patient
Background. Improvements in long-term kidney graft sur-
survival [1]. A recent analysis of the UNOS/OPTN trans-vival have been recently noted. However, the reasons for this
plant database, confirmed that long-term renal graft sur-were unclear. This study examined post-transplant renal func-
tion within the first year as an independent variable influencing vival measured as graft half-life has improved from 1988
long-term survival. to 1996 [2]. Many risk factors are known to influence long-
Methods. The influence of demographic characteristics (age,
term graft survival. Among these include: recipient age,sex, race); transplant variables (cadaver versus living donor,
race, presence of diabetes, delayed graft function (DGF),cold ischemia time, HLA mismatching, delayed graft function
and transplant year), and post-transplant variables (immuno- HLA mismatching, and acute rejection episodes [2–4].
suppressive agents for the prevention of acute rejection, clinical Improvement in half-life was seen even after an adjust-
acute rejection and post-transplant renal function in the first
ment for these risk factors, indicating that additional,year) on graft survival were analyzed for 105,742 adult renal
unidentified factors remain.transplants between 1988 and 1998. Renal function in the first
year was expressed as serum creatinine at six months and one Renal function within the first year of transplantation
year and delta creatinine (change in serum creatinine between also has been reported to an important factor influencing
6 months and 1 year). Graft half-life was used to measure long-
graft survival [4–8]. Previous studies that examined renalterm survival.
function have either been from a single center in the con-Results. During this 11-year period, the one-year serum cre-
atinine values for cadaver recipients steadily improved, from text of acute rejection episode or have utilized discharge
1.82  0.82 mg/dL in 1988 to 1.67  0.82 mg/dL in 1998 (P  creatinine values [4–8]. Therefore, it has not been possi-0.001), as did the graft half-life. There was a progressive decline
ble to separate the effects of renal function and otherin graft half-life for each incremental increase of six month,
confounding variables such as acute rejection and DGF.one year and  creatinine for living and cadaver donor trans-
plants as well for cadaver transplants with donor age  and The purpose of this study was to examine renal func-
50 years. The Relative Hazard (RH) for graft failure was tion in the first year of transplantation as an independent1.63 (1.61, 1.65; P  0.0001) with each increment of 1.0 mg/dL
variable in determining long-term renal graft survival.of serum creatinine at one year post-transplant and it increased
to 2.26 (2.2, 2.31; P  0.0001) when the  creatinine was Our hypothesis was that preservation of renal function
0.5 mg/dL. The RH reduction for graft failure was substantially in the first year might provide additional explanation for
lower for the years 1993, 1996, 1997 and 1998 when post- improvements in graft half-life that have been noted re-transplant renal function was not included in the model (P 
cently. To accomplish this we reviewed 105,742 adult0.05). However, the RH reduction per year was not different
when post-transplant creatinine was included in the model, renal transplants in the United States performed be-
1.01 (0.94 to 1.05; P  0.89). tween 1988 and 1998.
Conclusion. In conclusion, one-year creatinine and  creati-
nine values predict long-term renal graft survival. Recent im-
provements in graft half-life are related to conservation of METHODSrenal function within the first year post-transplantation.
All adult recipients who underwent primary or repeat
renal transplantation with a graft from living and cadav-Key words: serum creatinine, graft survival, renal transplant, cadaveric
grafts, living donor grafts. eric donors in the United States between January 1988
and December 1998 were studied. Data were obtainedReceived for publication November 26, 2001
from all 256 kidney transplant programs as reported toand in revised form February 19, 2002
Accepted for publication February 21, 2002 the Organ Procurement and Transplantation Network/
United Network for Organ Sharing (OPTN/UNOS). 2002 by the International Society of Nephrology
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These data were analyzed according to the methodology
defined in this section. Patients who had multiorgan
transplants such as kidney/pancreas and pediatric recipi-
ents (age18 years) were excluded. These patients were
followed until November 2000.
Post-transplant renal function considered in this study
was defined as: serum creatinine at six months and one
year and  creatinine (the change in creatinine from
6 months to 1 year). Patients were stratified into six
groups according to their six month and one year post-
transplant serum creatinine values: 1.0, 1–1.5, 1.6–2.0,
2.1–2.5, 2.6–3.0 and 3.0 mg/dL. They were also divided
into seven groups, according to their  creatinine value:
0.1, 0.1–0.2, 0.3–0.4, 0.5–0.9, 1.0–1.9, 2.0–2.9, and 3.0
Fig. 1. Kaplan-Meier estimates for graft survival for each year aftermg/dL. Patients were further stratified according to or- cadaveric renal transplantation.
gan source: living and cadaver donor transplants, and
cadaver donor transplants according to donor age and
50 years. The Kaplan-Meier method was used to esti-
RESULTSmate graft survival [9]. A maximum likelihood estimate
of the projected half-life (median value) was calculated A total of 105,742 adult renal transplants (77,582 ca-
assuming exponentially distributed graft survival times. daver and 28,160 living donor transplants) performed in
Additional analyses were performed after censoring pa- the United States between 1988 and 1998 were included
tients who died while their grafts were functioning. in this study. Of these, 18,589 cadaver transplants were
The demographic variables used for covariate-adjusted performed using kidneys from donors50 years. The one-
analyses included age, sex, and race of the recipient and year graft survival rate for living donor transplants in
the donor. Other recipient variables included prior trans- 1988 was 89.7%. This improved to 94.3% in 1998, an in-
plantation, pre-transplant blood transfusions, titer of se- crement of 4.6 percentage points. During the same period
rum panel reactive antibody (PRA) in the recipient, graft survival rates for cadaver donor transplants im-
whether or not the patient received maintenance dialysis proved from 76.0% to 89.3%, an increase of 13.3 percent-
prior to transplant and associated medical conditions age points. Figure 1 shows the Kaplan-Meier estimates
such as diabetes as the cause for end-stage renal failure of survival of renal grafts for cadaver transplant for each
(ESRF). Transplant variables included the source of or- year from 1988 to 1998. The cohorts of patients trans-
gan (living or cadaveric donor), duration of cold ischemia planted in recent years have better short and long-term
time, extent of HLA mismatching, presence or absence survival rates than patients transplanted in early years.
of delayed graft function (DGF; defined as post-trans- Figure 2 shows the Kaplan-Meier estimates for ca-
plant dialysis within one week after transplant) and year daver grafts survival according to six month creatinine
in which transplant was performed. Post-transplant vari- (Fig. 2A), one year creatinine (Fig. 2B) and  creatinine
ables included use of antibody induction, discharge main- (Fig. 2C) values. Post-transplant creatinine 1.5 mg/dL
tenance immunosuppression with mycophenolate mo- at six months and one year, and  creatinine0.3 mg/dL
fetil or tacrolimus, clinical acute rejection within one year were associated with a decline in long-term graft survival.
and post-transplant renal function as previously defined. Similar survival patterns were noted for living donor
The analyses were performed with and without post- grafts as well for cadaver donor grafts from donors 
transplant renal function to assess whether transplant and 50 years of age (not shown). Table 1 shows the
year and post-transplant renal function are surrogates graft half-life for various post-transplant renal function
for each other. groups, with and without censoring for death with a
The multivariate analyses were performed using pro- functioning graft. These are stratified according to organ
portional hazards regression models adjusted for all vari- source (living and cadaver donor transplants) as well as
ables listed above. The relative hazard (RH) for long- cadaver donor age (donor age  and 50 years). A
term graft failure conditioned on survival to one year decline in graft half-life was noted with progressive in-
and corresponding 95% confidence intervals (CI) were creases in six month and one year creatinine values as
estimated. Reporting bias associated with rapid notifica- well as with increasing  creatinine values.
tion of critical events (graft failure, death) and delayed The mean creatinine (SD) values at six months and
notification for continued survival was not accounted for one year declined over time. For example, mean creati-
nine at one year decreased for living donor transplantsin this analysis.
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Fig. 2. Kaplan-Meier estimates after cadaveric renal transplantation
according to six month (A), one year (B), and  creatinine (C) values
post-transplantation.
from 1.65  0.89 mg/dL in 1988 to 1.55  0.67 mg/dL There were differences in demographic and post-trans-
plant variables for cadaveric recipients with one yearin 1998 (P  0.001). During the same period similar
changes in renal function were noted for cadaver trans- creatinine and1.5 mg/dL as shown in Table 2. Those
with elevated creatinine at one year (serum creatinineplants: 1.82  0.82 to 1.67  0.82 mg/dL (P  0.001),
cadaver donor transplants with donor age 50 years 1.5 mg/dL) were more likely to be male, black and
have had a previous transplant. They were less likely1.76 0.79 to 1.58 0.77 mg/dL (P  0.001), and donor
age 50 years 2.34  0.93 to 1.99  0.87 mg/dL (P  to have the diagnosis of diabetes than recipients with
creatinine 1.5 mg/dL at one year. Donor factors were0.001). Figure 3 shows the cumulative distribution of
one-year serum creatinine values for cadaveric recipients also different: those with elevated creatinine levels were
more likely have been recipients of a kidney from afor 1988 and 1997. The distribution of serum creatinine
was much lower in the cohort of patients transplanted female donor, black donor, or an older donor. Recipients
with creatinine 1.5 mg/dL at one year were also morein 1997. Similar trends were observed for serum creati-
nine at six months post-transplant and in  creatinine likely to have cold ischemia time24 hours, DGF, clini-
cal acute rejection within one year, and less likely to have(data not shown) values.
Figure 4 shows the projected median graft half-life for received a zero-mismatched kidney. Similar differences
were noted in patients who had living donor transplanteach year for all cadaver transplants and for cadaver
transplants according to one year creatinine values ( (data not shown). Thus, demographic variables such as
donor/recipient age, sex, and race and transplant vari-and 1.5 mg/dL). Overall improvement in half-life was
seen for cadaver transplants from 7.9 (7.6, 8.2) in 1988 ables such as cold ischemia time, DGF and acute rejec-
tion are key factors contributing to elevated creatinineto 11.2 (10.1, 12.2) years in 1997, an increase of 42%.
During the same period, the improvements in half-life after transplantation.
Figure 5 shows the graft half-life for cadaver recipientsin cadaver transplants with creatinine 1.5 mg/dL was
6.2 (5.9, 6.5) to 7.5 (6.7, 8.4) years, an increase of 21%, according to the combination of one year creatinine (
and 1.5 mg/dL) and  creatinine ( and 0.3 mg/dL)and for one year creatinine 1.5 mg/dL, was from 10.9
(10.2, 11.7) to 19 (15.9, 22.1) years, an increase of 74%. along with the presence or absence of prior clinical acute
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Table 1. Projected median graft half-life in years with 95% CI according to 6 month and 1 year post-transplant creatinine values
Cadaveric donors
Living donors All cadaveric donors Donor age 50 Donor age 50
6 Month creatinine mg/dL (N) (24,512) (63,106) (52,045) (11,061)
1.0 19.9 (16.8, 23.0) 12.3 (11.3, 13.3) 12.6 (11.5, 13.6) 7.1 (4.5, 9.7)
1.1–1.5 18.0 (17.2, 18.9) 11.5 (11.2, 11.8) 11.7 (11.4, 12.0) 9.5 (8.7, 10.3)
1.6–2.0 13.3 (12.6, 14.1) 8.8 (8.6, 9.1) 9.1 (8.8, 9.4) 7.5 (7.1, 8.0)
2.1–2.5 8.9 (8.1, 9.6) 6.6 (6.4, 6.9) 6.8 (6.5, 7.1) 6.2 (5.8, 6.6)
2.6–3.0 6.1 (5.3, 6.9) 4.8 (4.5, 5.0) 5.0 (4.7, 5.4) 4.3 (3.9, 4.7)
3.0 3.2 (2.8, 3.7) 3.2 (3.1, 3.4) 3.5 (3.2, 3.7) 2.9 (2.7, 3.2)
6 Month creatinine mg/dL
Death with a functioning graft
1.0 36.8 (29.0, 44.6) 26.4 (23.3, 29.6) 26.8 (23.5, 30.0) 18.8 (7.7, 29.9)
1.1–1.5 30.3 (28.4, 32.2) 20.9 (20.2, 21.6) 21.1 (20.3, 21.8) 19.0 (16.7, 21.2)
1.6–2.0 19.1 (17.9, 20.3) 14.1 (13.6, 14.6) 14.3 (13.8, 14.9) 13.1 (12.1, 14.2)
2.1–2.5 11.8 (10.6, 12.9) 9.3 (8.9, 9.7) 9.3 (8.8, 9.7) 9.3 (8.5, 10.1)
2.6–3.0 7.6 (6.4, 8.7) 6.0 (5.7, 6.4) 6.5 (6.0, 7.0) 5.3 (4.8, 5.8)
3.0 3.8 (3.2, 4.4) 3.9 (3.7, 4.1) 4.2 (3.8, 4.5) 3.5 (3.2, 3.8)
1 Year creatinine mg/dL
1.0 21.1 (17.6, 24.5) 14.0 (12.8, 15.1) 14.0 (12.8, 15.2) 11.8 (5.6, 18.0)
1.1–1.5 20.8 (19.7, 21.8) 13.2 (12.8, 13.5) 13.3 (12.9, 13.6) 11.9 (10.8, 13.1)
1.6–2.0 14.6 (13.8, 15.4) 9.4 (9.2, 9.7) 9.7 (9.4, 10.0) 8.3 (7.8, 8.9)
2.1–2.5 8.8 (8.1, 9.6) 6.4 (6.2, 6.7) 6.5 (6.2, 6.7) 6.4 (6.0, 6.9)
2.6–3.0 5.1 (4.5, 5.7) 4.5 (4.3, 4.7) 4.3 (4.1, 4.6) 4.8 (4.4, 5.2)
3.0 2.3 (2.1, 2.6) 2.4 (2.3, 2.5) 2.3 (2.2, 2.4) 2.7 (2.5, 2.9)
1 Year creatinine mg/dL
Death with a functioning graft (N) (22,712) (57,971) (48,054) (9917)
1.0 42.7 (32.6, 52.8) 30.7 (26.8, 34.5) 30.9 (27.0, 34.8) 23.6 (6.1, 41.1)
1.1–1.5 38.0 (35.3, 40.7) 25.8 (24.9, 26.8) 25.7 (24.7, 26.8) 27.1 (23.1, 31.0)
1.6–2.0 21.4 (20.0, 22.9) 15.4 (14.9, 16.0) 15.5 (14.9, 16.1) 15.1 (13.7, 16.4)
2.1–2.5 11.4 (10.3, 12.4) 9.0 (8.6, 9.4) 8.8 (8.3, 9.2) 9.8 (8.9, 10.7)
2.6–3.0 6.2 (5.3, 7.0) 5.8 (5.5, 6.1) 5.6 (5.2, 6.0) 6.3 (5.6, 6.9)
3.0 2.6 (2.3, 2.9) 2.8 (2.6, 2.9) 2.6 (2.4, 2.7) 3.1 (2.9, 3.3)
 Creatinine from 6 months to 1 year
0.1 17.3 (16.5, 18.1) 10.7 (10.5, 11.0) 11.3 (11.1, 11.6) 8.0 (7.6, 8.4)
0.1–0.2 16.6 (15.4, 17.8) 10.6 (10.2, 11.0) 11.1 (10.7, 11.6) 7.9 (7.1, 8.6)
0.3–0.4 13.1 (12.0, 14.3) 7.7 (7.3, 8.0) 8.1 (7.7, 8.5) 6.2 (5.6, 6.7)
0.5–0.9 7.9 (7.2, 8.7) 5.4 (5.1, 5.6) 5.8 (5.5, 6.1) 4.3 (3.9, 4.6)
1.0–1.9 3.3 (2.8, 3.7) 2.6 (2.4, 2.8) 2.7 (2.5, 2.9) 2.3 (2.0, 2.6)
2.0–2.9 1.7 (1.2, 2.1) 1.4 (1.2, 1.5) 1.3 (1.1, 1.4) 1.7 (1.3, 2.2)
3.0 1.1 (0.8, 1.4) 1.1 (0.9, 1.2) 1.1 (0.9, 1.2) 1.2 (0.8, 1.5)
 Creatinine
Censor for death with a functioning graft
0.1 27.7 (26.1, 29.3) 18.2 (17.6, 18.7) 19.3 (18.7, 19.9) 12.9 (12.1, 13.7)
0.1–0.2 25.7 (23.5, 28.0) 18.0 (17.1, 18.9) 19.0 (18.0, 20.0) 13.1 (11.6, 14.6)
0.3–0.4 19.9 (17.7, 22.1) 11.7 (11.1, 12.4) 12.6 (11.8, 13.4) 9.0 (8.0, 10.0)
0.5–0.9 10.4 (9.3, 11.6) 7.4 (7.0, 7.8) 7.9 (7.4, 8.4) 6.0 (5.4, 6.6)
1.0–1.9 3.8 (3.3, 4.4) 3.1 (2.9, 3.3) 3.2 (2.9, 3.5) 2.9 (2.5, 3.2)
2.0–2.9 1.8 (1.3, 2.3) 1.5 (1.3, 1.7) 1.4 (1.2, 1.6) 1.9 (1.4, 2.4)
3.0 1.2 (0.8, 1.5) 1.2 (1.0, 1.3) 1.2 (1.0, 1.3) 1.2 (0.8, 1.6)
rejection. Recipients with creatinine 1.5 mg/dL with  Similarly, older donor age and black donor race in-
creased the risk of long-term failure. Living donor trans-creatinine 0.3 mg/dL have a substantially lower pro-
jected graft half-life than all other groups regardless of plant recipients had a decreased risk of graft failure.
Transplant variables such as increasing HLA mismatchprior acute rejection. Rejection episodes had greatest
impact for recipients with serum creatinine 1.5 and  level and DGF also were associated with increased risk
of graft failure.creatinine 0.3 mg/dL.
The results of the proportional hazard analysis are There was also a significant interaction between the dif-
ferent measures of post-transplant renal function as shownshown in Table 3. The parameter estimate, RH, 95% CI,
and P value are shown for each recipient, donor, trans- in Figure 6. Serum creatinine increment of 1.0 mg/dL, at
one year post-transplant without a change in  creati-plant, and post-transplant characteristic included in the
final model. Some significant factors that increased the nine, increased RH of graft failure to 1.63 (1.61, 1.65;
P  0.0001). However, when this was accompanied withrisk of graft failure include recipient variables such as
older age, black race, diabetes, and previous transplant. a change in  creatinine of 0.5 and 1.0 mg/dL, the RH
Hariharan et al: Long-term graft survival 315
long-term graft survival [3, 4, 10]. However, improve-
ments in long-term graft survival have been noted even
after correcting for these variables [2]. Serum creatinine
is not a reliable method for estimating renal function;
as it dependent on age, gender, race and body weight.
However, these variables were included in the Cox
model analysis. From the current study, post-transplant
renal function within the first year emerges as an impor-
tant variable, which influences long-term graft survival.
Other key variables for long-term outcome are: donor
source (living vs. cadaver), donor age, recipient race and
presence of diabetes. When renal function was intro-
duced in the Cox model for late graft failure, the decline
in RH between 1988 and 1997 was nullified. This indi-
Fig. 3. Cumulative distribution of one-year serum creatinine values for cated that the improvements in half-life in recent years
cadaveric recipients transplanted in 1988 () and 1997 (). are in part due to better preservation of renal function
within the first year.
In the current analysis, a progressive decline in graft
survival rates was noted for all groups, with and withoutof graft failure increased to 2.26 (2.2, 2.31) and 3.13 (2.99,
censoring for death with a functioning graft, when the3.27; P  0.0001), respectively. Thus, increases in both
one year creatinine value was1.5 mg/dL or creatininethe serum creatinine value at one year and in the  cre-
was0.3 (Table 1). The improved half-life in recent yearsatinine resulted in progressively increasing risks of graft
was seen predominantly in those patients with a one yearfailure. The relatively large values of RH for the com-
creatinine value1.5 (Fig. 4). Since 1988, there has beenbination of these effects indicate the importance of these
a gradual decline in mean creatinine values at one yearfactors together in predicting long-term graft survival.
post-transplantation for all groups. The cumulative dis-When post-transplant renal function was included
tribution of one-year serum creatinine has improved inin the model, the RH reduction per year was 1.01 (0.94
1997 compared to 1988 (Fig. 3). There also has been ato 1.05; P  0.89). However, if post-transplant renal
gradual reduction in acute rejection episodes over timefunction was excluded, transplants performed in 1993,
[2]. However, when renal function within the first year1996, 1997, and 1998 had reduced RH of graft failure
and clinical acute rejection were included in the regres-compared to transplants performed in other years (1988
sion model for long-term graft failure, it was the oneto 1992, 1994, and 1995; P  0.05). Because the effect
year creatinine and  creatinine values that were signifi-of transplant year was no longer significant when post-
cant, and not the clinical acute rejection episodes (Ta-transplant renal function was included in the model, it
ble 3). Stratification of cadaveric recipients in this study,is clear that these variables are surrogates for one an-
according to one year creatinine ( or 1.5 mg/dL),other, and improved graft survival rate in recent years
 creatinine (0.3 or 0.3) values and clinical acuteis due to improved post-transplant renal function during
rejection, revealed that renal function is the most impor-the same time.
tant predictor of graft survival (Fig. 5). Thus, in the
setting of acute rejection, it is the preservation of renal
DISCUSSION function that is more important for graft survival.
In previous studies, discharge creatinine was identifiedThe current shortage of organs for transplantation un-
derscores the importance of optimizing long-term graft as a strong predictor of transplant survival [4]. The pro-
jected median graft half-life for cadaveric transplantssurvival. Since1988, there has been a gradual improve-
ment in one-year graft survival. Thus, in recent years with discharge creatinine values of 0.5 to 1.5 mg/dL was
11.5 years. Half-life values for patients with dischargethere are more patients with a functioning graft at the
end of one year post-transplant. There has also been a serum creatinine 1.6 to 2.5 and2.5 mg/dL were 9.6 and
7.2 years, respectively. Discharge creatinine has limitedsteady improvement in graft half-life [2]. This has oc-
curred despite increasing use of older donors. During value as many patients are discharged within a few days
after transplant, before they reach nadir creatinine levels.the period between 1988 and 1997 there also has been
a gradual reduction in acute rejection episodes, which is This is true especially for recipients of renal transplants
from older donors, those with prolonged cold ischemiaan important predictor for late graft failure [2]. Other
variables such as recipient and donor age, elevated PRA, time and those who experience DGF. One-month creati-
nine values may be falsely elevated due to higher cyclo-pre-transplant dialysis requirements, presence of diabe-
tes and DGF are known to have a detrimental effect on sporine and tacrolimus levels used to prevent acute rejec-
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Fig. 4. Projected median kidney half-life for
all cadaveric renal grafts for each year ()
and those with one year creatinine values 
( ) and  ( ) 1.5 mg/dL.
Table 2. Summary of recipient, donor and transplant variables (%)
for cadaveric transplants associated with elevated
1 year serum creatinine
1 Year serum creatinine
1.5 mg/dL 1.5 mg/dL P value
Recipient variables
Male 49.4 71.8 0.0001
Black 19.3 29.7 0.0001
Diabetes 22.1 18.4 0.0001
Previous transplant 13.9 15.8 0.0001
Donor variables
Male 67.8 56.6 0.0001
Black 9.2 10.3 0.0001
Age 50 9.3 28.3 0.0001
Transplant variables
Cold ischemia time 24 hours 34.2 38.3 0.0001
Delayed graft function 16.2 26.9 0.0001
Clinical acute rejection 30.2 31.7 0.0001 Fig. 5. Projected median graft half-life for cadaveric renal grafts ac-
Zero mismatch 12.1 9.1 0.0001 cording to one year creatinine ( or 1.5 mg/dL),  creatinine (0.3
or 0.3 mg/dL) and presence () or absence () of clinical acute
rejection within one year post-transplantation.
tion. Hence, this study used six month and one year
creatinine values to predict long-term graft survival. associated with poorer graft survival [10, 11]. First of all,
there are known factors that influence long-term out-Other investigators using single center studies have
noted a strong correlation between serum creatinine at come, such as occurrence of acute rejection, incidence of
DGF and HLA mismatching, which have changed favor-three and six months [5] and at one year with long-
term survival [6]. Similarly, a  creatinine of 0.5 or ably over time. In addition, it is likely that acute rejection
episodes have been treated effectively since 1988, thereby1.0 mg/dL at six weeks or the pattern of creatinine
response after acute rejection have been correlated to preserving renal function and increasing kidney half-life.
Treatment and prevention of subclinical acute rejectionlong-term graft failure [7, 8]. In the current study, all
patients transplanted in the US over 11 years were in- has been noted to preserve renal function over time [12].
It is also possible that cyclosporine/tacrolimus nephro-cluded in the analysis. This provided an opportunity for
a more comprehensive analysis to examine the effects toxicity has diminished over time. Finally, other factors
such as optimizing the use of kidneys from older donorsof individual variables such as acute rejection episodes,
transplant year and post-transplant renal function on [10, 11], better management of DGF [3, 4, 13], and bet-
ter control of hypertension and hyperlipidemia may con-long-term graft survival.
There may be several reasons for the improvement tribute to the preservation of renal function during the
first year post-transplantation. The long-term survival im-in renal function over time during the first year after
transplantation. The improvement has occurred despite provements in recent years appear to be due to enhanced
one-year graft survival (Fig. 1). However, on further care-increasing reliance on older donors, which are generally
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Table 3. Cox proportional hazard model results: Risks for long-term graft failure
Variables Parameter estimate RH 95% Confidence interval P value
Recipient variables
Recipient age
Linear 0.0696 0.0001
Quadratic 0.0770 0.0001
53 vs. 43 years 1.07 (1.06, 1.08)
Recipient female 0.0970 1.10 (1.07, 1.13) 0.0001
Recipient black 0.3412 1.41 (1.36, 1.46) 0.0001
Diabetes 0.4653 1.59 (1.54, 1.65) 0.0001
Hypertensive nephropathy 0.2117 1.24 (1.19, 1.29) 0.0001
Pre-TX dialysis 0.1950 1.22 (1.16, 1.27) 0.0001
Pre-TX transfusions 0.0577 1.06 (1.03, 1.09) 0.0001
Previous transplant 0.3193 1.38 (1.32, 1.43) 0.0001
Most recent PRA 80% 0.1552 1.17 (1.06, 1.28) 0.0010
Donor variables
Donor age 50a 0.2109 1.23 (1.14, 1.34) 0.0001
Donor black 0.1398 1.15 (1.10, 1.20) 0.0001
Transplant variables
HLA mismatch levela 0.0512 1.05 (1.04, 1.06) 0.0001
Delayed graft function 0.1506 1.16 (1.12, 1.20) 0.0001
Living donor transplant 	0.2227 0.80 (0.77, 0.83) 0.0001
Donor age50 and HLA mismatcha 	0.0263 0.97 (0.95, 1.00) 0.0243
Post-transplant variables
Acute rejection within 1 year 	0.0022 1.00 (0.97, 1.03) 0.8853
Any induction therapy 0.0125 1.01 (0.98, 1.04) 0.4018
Mycophenolate mofetil (MMF) 	0.0041 1.00 (0.94, 1.06) 0.8975
Tacrolimus 0.0282 1.03 (0.95, 1.11) 0.4841
Serum creatinine at 1 yearb 0.4865 1.63 (1.61, 1.65) 0.0001
 creatinine 1 yr-6 mob 0.7409 2.26 (2.2, 2.31) 0.0001
1 Year creatinine &  creatinineb 	0.0874 0.0001
a Due to the interaction, these terms must be considered in combination to determine all values of the relative hazard function
b See illustration of the interaction between 1 year creatinine and  creatinine in Figure 6
quality of renal function (creatinine1.5 mg/dL at 1 year)
should be implemented as a newer endpoint for primary
comparative trials.
In conclusion, one year creatinine and  creatinine
values are the variables that correlate best with long-
term renal graft survival. Recent improvements in graft
half-life for the United States can be attributed to better
preservation of renal function within the first year after
transplantation.
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